Examination of potential modifiers of the association of APOL1 alleles with CKD progression

Clinical Journal of the American Society of Nephrology

Volumn 10, Issue 12, 2015, Pages 2128-2135

  Chen, Teresa K ^a   Choi, Michael J ^a   Kao, W H Linda ^b,c   Astor, Brad C ^d   Scialla, Julia J ^e   Appel, Lawrence J ^a,b,c   Li, Liang ^f   Lipkowitz, Michael S ^g   Wolf, Myles ^h   Parekh, Rulan S ⁱ   Winkler, Cheryl A ^j   Estrella, Michelle M ^a,b   Crews, Deidra C ^a,b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^d UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^e DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^g GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h NORTHWESTERN UNIVERSITY   (United States)

ⁱ HOSPITAL FOR SICK CHILDREN   (Canada)

^j NATIONAL CANCER INSTITUTE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN; APOLIPOPROTEIN L1; HIGH DENSITY LIPOPROTEIN; UNCLASSIFIED DRUG; APOL1 PROTEIN, HUMAN; BIOLOGICAL MARKER; CREATININE; GENETIC MARKER;

ADULT; ALLELE; ARTICLE; BODY MASS; CHOLESTEROL BLOOD LEVEL; CHRONIC KIDNEY FAILURE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISEASE COURSE; FEMALE; GENETIC ASSOCIATION; GENETIC HETEROGENEITY; GENETIC RISK; GENETIC VARIABILITY; GLOMERULUS FILTRATION RATE; HEMATOCRIT; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OBESITY; POTASSIUM URINE LEVEL; RISK FACTOR; SODIUM URINE LEVEL; UREA NITROGEN BLOOD LEVEL; URINARY EXCRETION; AFRICAN AMERICAN; BLOOD; CLINICAL TRIAL; EPIDEMIOLOGY; ETHNOLOGY; GENE FREQUENCY; GENETIC ASSOCIATION STUDY; GENETIC MARKER; GENETIC PREDISPOSITION; GENETICS; GENOTYPE ENVIRONMENT INTERACTION; INCIDENCE; KIDNEY FAILURE, CHRONIC; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; PHENOTYPE; PROPORTIONAL HAZARDS MODEL; PROTECTION; RANDOMIZED CONTROLLED TRIAL; RENAL INSUFFICIENCY, CHRONIC; SOCIOECONOMICS; TIME FACTOR; UNITED STATES; UPREGULATION;

ADULT; AFRICAN AMERICANS; APOLIPOPROTEINS; BIOMARKERS; CREATININE; DISEASE PROGRESSION; FEMALE; GENE FREQUENCY; GENE-ENVIRONMENT INTERACTION; GENETIC ASSOCIATION STUDIES; GENETIC MARKERS; GENETIC PREDISPOSITION TO DISEASE; HUMANS; HYPERTENSION; INCIDENCE; KIDNEY FAILURE, CHRONIC; LIPOPROTEINS, HDL; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; OBESITY; PHENOTYPE; PROPORTIONAL HAZARDS MODELS; PROTECTIVE FACTORS; RENAL INSUFFICIENCY, CHRONIC; RISK FACTORS; SOCIOECONOMIC FACTORS; TIME FACTORS; UNITED STATES; UP-REGULATION;

EID: 84957798794     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.05220515     Document Type: Article

References (41)

1. Parsa A, Kao WH, Xie D, Astor BC, Li M, Hsu CY, Feldman HI, Parekh RS, Kusek JW, Greene TH, Fink JC, Anderson AH, Choi MJ, Wright JT Jr., Lash JP, Freedman BI, Ojo A, Winkler CA, Raj DS, Kopp JB, He J, Jensvold NG, Tao K, Lipkowitz MS, Appel LJ; AASK Study Investigators; CRIC Study Investigators: APOL1 risk variants, race, and progression of chronic kidney disease. NEnglJ Med369: 2183-2196, 2013.
2. Tzur S, Rosset S, Shemer R, Yudkovsky G, Selig S, Tarekegn A, Bekele E, Bradman N, Wasser WG, Behar DM, Skorecki K: Missense mutations in the APOL1 gene are highly associated with end stage kidney disease risk previously attributed to the MYH9 gene. Hum Genet 128: 345–350, 2010.
3. Genovese G, Friedman DJ, Ross MD, Lecordier L, Uzureau P, Freedman BI, Bowden DW, Langefeld CD, Oleksyk TK, Uscinski Knob AL, Bernhardy AJ, Hicks PJ, Nelson GW, Vanhollebeke B, Winkler CA, Kopp JB, Pays E, Pollak MR: Association of trypanolytic ApoL1 variants with kidney disease in AfricanAmericans. Science 329: 841–845, 2010.
4. Foster MC, Coresh J, Fornage M, Astor BC, Grams M, Franceschini N, Boerwinkle E, Parekh RS, Kao WH: APOL1 variants associate with increased risk of CKD among African Americans. J Am Soc Nephrol 24: 1484–1491, 2013.
5. Lipkowitz MS, Freedman BI, Langefeld CD, Comeau ME, Bowden DW, Kao WH, Astor BC, Bottinger EP, Iyengar SK, Klotman PE, Freedman RG, Zhang W, Parekh RS, Choi MJ, Nelson GW, Winkler CA, Kopp JB; SK Investigators: Apolipoprotein L1 gene variants associate with hypertension-attributed nephropathy and the rate of kidney function decline in African Americans. Kidney Int 83: 114–120, 2013.
6. Kopp JB, Nelson GW, Sampath K, Johnson RC, Genovese G, An P, Friedman D, Briggs W, Dart R, Korbet S, Mokrzycki MH, Kimmel PL, Limou S, Ahuja TS, Berns JS, Fryc J, Simon EE, Smith MC, Trachtman H, Michel DM, Schelling JR, Vlahov D, Pollak M, Winkler CA: APOL1 genetic variants in focal segmental glomerulosclerosis and HIV-associated nephropathy. J Am Soc Nephrol 22: 2129–2137, 2011.
7. Freedman BI, Kopp JB, Langefeld CD, Genovese G, Friedman DJ, Nelson GW, Winkler CA, Bowden DW, Pollak MR: The apolipoprotein L1 (APOL1) gene and nondiabetic nephropathy in African Americans. J Am Soc Nephrol 21: 1422–1426, 2010.
8. Freedman BI, Skorecki K: Gene-gene and gene-environment interactions in apolipoprotein L1 gene-associated nephropathy. Clin J Am Soc Nephrol 9: 2006–2013, 2014.
9. Kalayjian RC, Lau B, Mechekano RN, Crane HM, Rodriguez B, Salata RA, Krishnasami Z, Willig JH, Martin JN, Moore RD, Eron JJ, Kitahata MM: Risk factors for chronic kidney disease in a large cohort of HIV-1 infected individuals initiating antiretroviral therapy in routine care. AIDS 26: 1907–1915, 2012.
10. Estrella MM, Li M, Tin A, Abraham AG, Shlipak MG, Penugonda S, Hussain SK, Palella FJ Jr., Wolinsky SM, Martinson JJ, Parekh RS, Kao WH: The association between APOL1 risk alleles and longitudinal kidney function differs by HIV viral suppression status. Clin Infect Dis 60: 646–652, 2015.
11. Divers J, Núñez M, High KP, Murea M, Rocco MV, Ma L, Bowden DW, Hicks PJ, Spainhour M, Ornelles DA, Kleiboeker SB, Duncan K, Langefeld CD, Turner J, Freedman BI: JC polyoma virus interacts with APOL1 in African Americans with nondiabetic nephropathy. Kidney Int 84: 1207–1213, 2013.
12. Tin A, Grams ME, Maruthur NM, Astor BC, Couper D, Mosley TH, Fornage M, Parekh RS, Coresh J, Kao WH: Hemostatic factors, APOL1 risk variants, and the risk of ESRDin the Atherosclerosis Risk in Communities Study. Clin J Am Soc Nephrol 10: 784–790, 2015.
13. Divers J, Palmer ND, Lu L, Langefeld CD, Rocco MV, Hicks PJ, Murea M, Ma L, Bowden DW, Freedman BI: Gene-gene interactions in APOL1-associated nephropathy. Nephrol Dial Transplant 29: 587–594, 2014.
14. Wright JT Jr., Bakris G, Greene T, Agodoa LY, Appel LJ, Charleston J, Cheek D, Douglas-Baltimore JG, Gassman J, Glassock R, Hebert L, Jamerson K, Lewis J, Phillips RA, Toto RD, Middleton JP, Rostand SG; African American Study of Kidney Disease and Hypertension StudyGroup: Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: Results from the AASK trial. JAMA 288: 2421–2431, 2002.
15. Appel LJ, Middleton J, Miller ER 3rd, Lipkowitz M, Norris K, Agodoa LY, Bakris G, Douglas JG, Charleston J, Gassman J, Greene T, Jamerson K, Kusek JW, Lewis JA, Phillips RA, Rostand SG, Wright JT: The rationale and design of the AASK cohort study. J Am Soc Nephrol 14[Suppl 2]: S166–S172, 2003.
16. Appel LJ, Wright JT Jr., Greene T, Agodoa LY, Astor BC, Bakris GL, Cleveland WH, Charleston J, Contreras G, Faulkner ML, Gabbai FB, Gassman JJ, Hebert LA, Jamerson KA, Kopple JD, Kusek JW, Lash JP, Lea JP, Lewis JB, Lipkowitz MS, Massry SG, Miller ER, Norris K, Phillips RA, Pogue VA, Randall OS, Rostand SG, Smogorzewski MJ, Toto RD, Wang X; AASK Collaborative Research Group: Intensive blood-pressure control in hypertensive chronic kidney disease. N Engl JMed 363: 918–929, 2010.
17. Patterson N, Hattangadi N, Lane B, Lohmueller KE, Hafler DA, Oksenberg JR, Hauser SL, Smith MW, O’Brien SJ, Altshuler D, Daly MJ, Reich D: Methods for high-density admixture mapping of disease genes. Am J Hum Genet 74: 979–1000, 2004.
18. Sika M, Lewis J, Douglas J, Erlinger T, Dowie D, Lipkowitz M, Lash J, Cornish-Zirker D, Peterson G, Toto R, Kusek J, Appel L, Kendrick C, Gassman J; AASK Group: Baseline characteristics of participants in the African American Study of KidneyDisease and Hypertension (AASK) Clinical Trial and Cohort Study. Am J Kidney Dis 50: 78–89.e1, 2007.
19. Scialla JJ, Appel LJ, Astor BC, Miller ER 3rd, Beddhu S, Woodward M, Parekh RS, Anderson CA; African American Study of Kidney Disease and Hypertension Study Group: Net endogenous acid production is associated with a faster decline in GFR in African Americans. Kidney Int 82: 106–112, 2012.
20. Frassetto LA, Todd KM, Morris RC Jr., Sebastian A: Estimation of net endogenous noncarbonic acid production in humans from diet potassiumand protein contents. AmJ ClinNutr 68: 576–583, 1998.
21. Scialla JJ, Appel LJ, Astor BC, Miller ER3rd, Beddhu S, Woodward M, Parekh RS, Anderson CA: Estimated net endogenous acid production and serum bicarbonate in African Americans with chronic kidney disease. Clin J Am Soc Nephrol 6: 1526–1532, 2011.
22. Scialla JJ, Astor BC, Isakova T, Xie H, Appel LJ, Wolf M: Mineral metabolites andCKDprogression inAfricanAmericans. J AmSoc Nephrol 24: 125–135, 2013.
23. Helal I, Fick-Brosnahan GM, Reed-Gitomer B, Schrier RW: Glomerular hyperfiltration: Definitions, mechanisms and clinical implications. Nat Rev Nephrol 8: 293–300, 2012.
24. Brenner BM, Meyer TW, Hostetter TH: Dietary protein intake and the progressive nature of kidney disease: The role of hemodynamically mediated glomerular injury in the pathogenesis of progressive glomerular sclerosis in aging, renal ablation, and intrinsic renal disease. N Engl JMed 307: 652–659, 1982.
25. Hostetter TH, Olson JL, Rennke HG, Venkatachalam MA, Brenner BM: Hyperfiltration in remnant nephrons: A potentially adverse response to renal ablation. Am J Physiol 241: F85–F93, 1981.
26. Wickman C, Kramer H: Obesity and kidney disease: Potential mechanisms. Semin Nephrol 33: 14–22, 2013.
27. Juraschek SP, Appel LJ, Anderson CA, Miller ER 3rd: Effect of a high-protein diet on kidney function in healthy adults: Results from the OmniHeart trial. Am J Kidney Dis 61: 547–554, 2013.
28. Jia G, Sowers JR: Autophagy: A housekeeper in cardiorenal metabolic health and disease. Biochim Biophys Acta 1852: 219–224, 2015.
29. Kosacka J, Kern M, Klöting N, Paeschke S, Rudich A, Haim Y, Gericke M, Serke H, Stumvoll M, Bechmann I, Nowicki M, Blüher M: Autophagy in adipose tissue of patients with obesity and type 2 diabetes. Mol Cell Endocrinol 409: 21–32, 2015.
30. Kovsan J, Blüher M, Tarnovscki T, Klöting N, Kirshtein B, Madar L, Shai I, Golan R, Harman-Boehm I, Schön MR, Greenberg AS, Elazar Z, Bashan N, Rudich A: Altered autophagy in human adipose tissues in obesity. J Clin Endocrinol Metab 96: E268–E277, 2011.
31. Nunez CE, Rodrigues VS, Gomes FS, Moura RF, Victorio SC, Bombassaro B, Chaim EA, Pareja JC, Geloneze B, Velloso LA, Araujo EP: Defective regulation of adipose tissue autophagy in obesity. Int J Obes 37: 1473–1480, 2013.
32. Fornoni A, Merscher S, Kopp JB: Lipid biology of the podocyte–new perspectives offer new opportunities. Nat Rev Nephrol 10: 379–388, 2014.
33. Vanhollebeke B, Pays E: The function of apolipoproteins L. Cell Mol Life Sci 63: 1937–1944, 2006.
34. Nichols B, Jog P, Lee JH, Blackler D, Wilmot M, D’Agati V, Markowitz G, Kopp JB, Alper SL, Pollak MR, Friedman DJ: Innate immunity pathways regulate the nephropathy gene Apolipoprotein L1. Kidney Int 87: 332–342, 2015.
35. Peev V, Nayer A, Contreras G: Dyslipidemia, malnutrition, inflammation, cardiovascular disease and mortality in chronic kidney disease. Curr Opin Lipidol 25: 54–60, 2014.
36. Gregor MF, Hotamisligil GS: Inflammatory mechanisms in obesity. Annu Rev Immunol 29: 415–445, 2011.
37. Bentley AR, Doumatey AP, Chen G, Huang H, Zhou J, Shriner D, Jiang C, Zhang Z, Liu G, Fasanmade O, Johnson T, Oli J, Okafor G, Eghan BA Jr., Agyenim-Boateng K, Adeleye J, Balogun W, Adebamowo C, Amoah A, Acheampong J, Adeyemo A, Rotimi CN: Variation in APOL1 contributes to ancestry-level differences in HDLc-kidney function association. Int J Nephrol 2012: 748-984, 2012.
38. Powe CE, Evans MK, Wenger J, Zonderman AB, Berg AH, Nalls M, Tamez H, Zhang D, Bhan I, Karumanchi SA, Powe NR, Thadhani R: Vitamin D-binding protein and vitamin D status of black Americans and white Americans. N Engl J Med 369: 1991–2000, 2013.
39. Jones G: Interpreting vitamin D assay results: Proceed with caution. Clin J Am Soc Nephrol 10: 331–334, 2015.
40. Bouillon R, Jones K, Schoenmakers I: Vitamin D-binding protein and vitaminDin blacks and whites. NEngl J Med 370: 879, 2014.
41. Chen Y: Vitamin D-binding protein and vitamin D in blacks and whites. N Engl J Med 370: 878–879, 2014.